SCHEMBL5453382

SCHEMBL5453382

Cc1ccc(-c2ccc(-c3c(N)nn4ccnc4c3N)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 3/20 0.37
SRC P12931 3/20 0.37
HPGD P15428 2/20 0.37
FYN P06241 2/20 0.37
LMNA P02545 2/20 0.37
KDR P35968 2/20 0.37
RIPK2 O43353 2/20 0.37
PLK4 O00444 1/20 0.37
ROCK2 O75116 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
EGFR P00533 1/20 0.37
ERBB2 P04626 1/20 0.37
INSR P06213 1/20 0.37
LCK P06239 1/20 0.37
CSF1R P07333 1/20 0.37
YES1 P07947 1/20 0.37
LYN P07948 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4709570 0.98 KDM4E (0.38) KDM4EALDH1A1SRCHPGDFYN
SCHEMBL4757863 0.86 NUDT1 (0.35) KDM4EALDH1A1HPGDKDRKMT2A
SCHEMBL4760688 0.83 NPC1 (0.41) KDM4EALDH1A1SRCHPGDLMNA
SCHEMBL4759759 0.70 JAK2 (0.35) JAK2JAK3
SCHEMBL13841956 0.67 MAPT (0.52) KDM4EALDH1A1HPGDLMNAKDR
SCHEMBL3703475 0.66 JAK2 (0.55) NPSR1NPC1MAPTJAK2JAK3
SCHEMBL13841955 0.65 MAOB (0.54) KDM4EALDH1A1LMNAKDRPLK4
SCHEMBL13178372 0.65 NPC1 (0.50) KDM4EALDH1A1LMNAKDRFLT3
SCHEMBL15308491 0.64 PIK3CG (0.49) ALDH1A1HPGDHSD17B10JAK2JAK3
SCHEMBL19766651 0.64 NUDT1 (0.41) KDM4EALDH1A1HPGDLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078136-A1 Fused heterocyclic compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078136-A1 Fused heterocyclic compounds useful as kinase modulators MAP3K2, MAP3K3, MAP4K2 KDM4E 853/4885ALDH1A1 3349/4885SRC 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.